The Hydropothecary Corporation (TSX:HEXO) recently introduced an intimate medical cannabis oil
SmallCapPower | July 23, 2018: The Hydropothecary Corporation (TSX:HEXO) announced on July 16, 2018, the launch of Fleur de Lune, an intimate medical cannabis oil. Fleur de Lune is an odorless and tasteless carrier oil. Fleur de Lune is a blend of THC oil and medium-chain triglyceride (MCT) oil, obtained through state-of-the-art oil extraction process.
For Our Complete Coverage Of Canadian Marijuana Stocks Click Here
Watch: Cannex Capital Holdings (CSE:CNNX) Wants to Emerge as a Multi-State U.S. Player, Says CEO
Fleur de Lune is another jewel in HEXO’s smoke-free product portfolio and is an epitome of cannabis oil innovation. Other products in the portfolio include Elixir CBD Peppermint and Elixir THC Peppermint, which are cannabis oil sublingual sprays. The Company is trying to capitalize on the smoke-free cannabis market. Other products include the Decarb line, which won Best New Cannabis Product at the Canadian Cannabis Awards 2017.
The oil is packaged in a 60ml bottle, which contains up to 600mg of THC, or 7 to 10mg/ml. The oil is priced at $59 for a 60ml spray bottle.
Hydropothecary CEO Sebastien St-Louis said, “With Fleur de Lune, we’re continuing to execute on our innovation and product development strategy. Fleur de Lune is yet another smoke-free medical cannabis option that responds to the evolving needs of our clients and the Canadian marketplace.”
Hydropothecary Vice-President of Sales Sonia Isabel said, “We’re excited to be launching intimate oil, which is a completely different use for medical cannabis. We believe Canadians will embrace this discreet way to consume their medicine.”
HEXO creates and distributes innovative, easy-to-use and easy-to-understand products to serve the Canadian cannabis market. Hydropothecary is rapidly increasing its production capacity in the lead up to the recreational adult-use cannabis market in Canada. The Company currently operates with 300,000 sq. ft. of production capacity and has another 1,000,000 sq. ft. expansion set to be completed by year end. Hydropothecary will serve the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand.
Hydropothecary trades at a market capitalization of $833.9 million with a price to book multiple of 2.66x. The strong smokeless portfolio should boost demand for the Company’s products, which will likely reflect positively on Hydropthecary Corp’s market capitalization.
Disclosure: Neither the author nor his family own shares in the company mentioned above.
To read our full disclosure, please click on the button below:
